Martínez‐González 2018.

Study characteristics
Methods	Study design: longitudinal cohort Country: Spain Data collection period: Baseline from January 2010 and 2‐year appointment at time of analysis (February 2016) Registry ID: ClinicalTrials.gov: NCT01122758
Participants	Number of participants: N = 1081; Number included in meta‐analysis: N = 188 Sample characteristics (at baseline): Age (mean): 65.2 years (SD 8.9); Sex (% male): 80.8% (873/1081) Population category: chronic physical condition; Specific population: data from CHAIN (COPD History Assessment in Spain), a Spanish multi‐centre study carried out at pulmonary clinics including people who actively or previously smoked with COPD Nicotine dependence: not measured; Baseline cigarettes per day: CPD per day not reported, pack years cohort 55.3 (SD 28.2); Motivation to quit: not selected by motivation to quit
Interventions	Behavioural support for smoking cessation: yearly minimal smoking cessation counselling offered during follow‐up, no other specific tobacco intervention was carried out to quit tobacco Pharmacological support for smoking cessation: no pharmacological support Psychotherapeutic or psychoactive support for mental health or mood: did not receive mood management
Outcomes	Definition of cessation used: 'those who stopped smoking at time of second visit and persisted without smoking until third visit’; smoking status was evaluated from the clinical history and it was confirmed by co‐oximetry Cessation definition used for outcome(s) in this analysis: continuous abstinence Measure of biovalidation: expired CO Definition of people who continued to smoke used: exact definition not reported; ‘those who continued smoking at all 3 visits’ Time point(s) at which follow‐up was conducted: 2 years Outcome category: Anxiety, Depression Outcome measure(s): Hospital Anxiety and Depression Scale (HADS)
Funding source	This study has been funded by AstraZeneca
Author conflicts of interest	C. C. has received speaker fees from Novartis, Menarini, Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline, and Teva, and consulting fees from AstraZeneca, Esteve, GlaxoSmithKline, and Novartis. B. G. C. has received speaker fees from AstraZeneca,Novartis, Menarini, and Chiesi. I. S. has received company training fees from Novartis and speaker fees from Esteve. J. L. L.‐C. has received honoraria for lecturing, scientific advice, participation in clinical studies or writing for publications for: Almirall, AstraZeneca, Bayer,Boehringer Ingelheim, Cantabria Pharma, Chiesi, Esteve, Faes, Ferrer, Gebro, GlaxoSmithKline, Grifols, Menarini, MSD, Novartis, Pfizer, Rovi, Teva and Takeda. None declared for the remaining authors
Notes	Outcome data source: Published data